|
Modification of Allergic Immunologic Response by Leukotriene Antagonists - Ancillary to ACRN IMPACT Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on Modification of Allergic Immunologic Response by Leukotriene Antagonists - Ancillary to ACRN IMPACT conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Modification of Allergic Immunologic Response by Leukotriene Antagonists - Ancillary to ACRN IMPACT Clinical research trials and Modification of Allergic Immunologic Response by Leukotriene Antagonists - Ancillary to ACRN IMPACT healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including Modification of Allergic Immunologic Response by Leukotriene Antagonists - Ancillary to ACRN IMPACT. Modification of Allergic Immunologic Response by Leukotriene Antagonists - Ancillary to ACRN IMPACT Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Modification of Allergic Immunologic Response by Leukotriene Antagonists - Ancillary to ACRN IMPACT clinical trial. Test subjects oftentimes recieve the best healthcare possible for their Modification of Allergic Immunologic Response by Leukotriene Antagonists - Ancillary to ACRN IMPACT condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "M" Clinical Trials Conditions > Modification of Allergic Immunologic Response by Leukotriene Antagonists - Ancillary to ACRN IMPACT  Modification of Allergic Immunologic Response by Leukotriene Antagonists - Ancillary to ACRN IMPACT
Modification of Allergic Immunologic Response by Leukotriene Antagonists - Ancillary to ACRN IMPACT
For Condition: Lung Diseases,Asthma
Status: No longer recruiting
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To examine the cellular and molecular mechanisms of corticosteroid and leukotriene receptor antagonists, focusing on their effects on T lymphocytes during both chronic (18 months) and acute therapy.
Details: BACKGROUND: Asthma is a chronic inflammatory disease. T lymphocytes are essential for initiating and maintaining the asthmatic inflammatory immune response. Corticosteroid treatment targets several inflammatory responses, including T lymphocytemediated responses. In addition, leukotriene receptor antagonists (LTRA) may influence T cell activation. To investigate the effects of these two controller agents in the treatment of asthma on airway function is the goal of the IMPACT clinical trial in mild chronic adult asthmatics. The Improving Asthma Control Trial (IMPACT) is one of the trials within the NHLBI-supported Asthma Clinical Research Network (ACRN). IMPACT is a double-blind, randomized, parallel group design clinical trial to determine the best long-term strategy for treating adults with mild asthma who experience symptoms more than occasionally. The trial will test whether these patients should be taking anti-inflammatory medications on a daily basis and whether a newer class of medications provides the same benefit as older drugs. In the IMPACT study, 234 adults with mild asthma who have more than occasional symptoms will be enrolled in six clinical research centers. Following an initial evaluation, patients will be randomized to receive either a twice daily inhaled corticosteroid, a twice daily anti-leukotriene, or a placebo. All patients will receive treatment for symptoms if and when they occur. The results should demonstrate whether medication is required on a daily basis by these patients, and if so, whether inhaled corticosteroids and leukotriene modifiers are equally effective. Recruitment began in May, 2000. The trial is expected to be completed in 2003. The study is in response to an initiative "Ancillary Studies in Heart, Lung, and Blood Disease Trials" released by the National Heart, Lung, and Blood Institute in June 2000. DESIGN NARRATIVE: A total of 39 patients, 13 in each arm, will be randomized to inhaled steroid, leukotriene receptor antagonist or placebo and followed for 18 months for changes in T-cell costimulatory pathways.
Eligibility:
Study Type: Observational, Longitudinal, Retrospective Study
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: No eligibility criteria
Total Enrollment:
Location and Contact Information:
Additional Information:
Study ID Numbers: 976;
Study Start Date: April 2001
Record last reviewed: October 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00021931
Other Lung Diseases Studies:
1. Occupation and Asthma in an Urban Low Income Population
2. Segmental Bronchoalveolar Lavage
3. Early Risk Predictors For Chronic Pulmonary Disease
4. Ozone and Rhinovirus-Induced Disease in Asthmatics
5. Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma
Related Studies:
Other Lung Diseases Clinical Trials
Other Clinical Trials
Other Clinical Trials
Modification of Allergic Immunologic Response by Leukotriene Antagonists - Ancillary to ACRN IMPACT
|
|
|
|
|
|
|
|
